Targeted drug delivery via the folate receptor

Advanced Drug Delivery Reviews

Volumn 41, Issue 2, 2000, Pages 147-162

  Sudimack, Jennifer ^a   Lee, Robert J ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Drug delivery systems; Endocytosis; Folate receptor; Gene therapy; Immunotherapy; Liposomes; Protein toxins; Radioimaging

Indexed keywords

CELLS; CHEMOTHERAPY; GENES; IMMUNOLOGY; MEDICAL IMAGING; MONOCLONAL ANTIBODIES; ONCOLOGY; PHARMACOKINETICS; PROTEINS;

ENDOCYTOSIS; FOLATE RECEPTOR; GENE THERAPY; IMMUNOTHERAPY; LIPOSOMES; PROTEIN TOXINS; TARGETED DRUG DELIVERY;

CONTROLLED DRUG DELIVERY;

CELL SURFACE RECEPTOR; CHIMERIC ANTIBODY; DIPHTHERIA TOXIN; FOLIC ACID; GALLIUM 67; INDIUM 111; IODINE 131; MOMORDIN; MONOCLONAL ANTIBODY; PSEUDOMONAS EXOTOXIN; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; VIRUS VECTOR;

CANCER DIAGNOSIS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; IMMUNOSCINTIGRAPHY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RECEPTOR BINDING; REVIEW;

ANIMALS; CARRIER PROTEINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; IMMUNOTOXINS; LIPOSOMES; NEOPLASMS; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RECEPTORS, CELL SURFACE;

EID: 0343882023     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00062-9     Document Type: Review

References (92)

1. Campbell I.G., Jones T.A., Foulkes W.D., Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res. 51:1991;5329-5338.
2. Coney L.R., Tomaselti A., Carayannopoulos L., et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res. 51:1991;6125-6132.
3. Franklin W.A., Waintrub M., Edwards D., et al. New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int. J. Cancer. 8:1994;89-95.
4. Garin-Chesa P., Campbell I., Saigo P., Lewis J., Old L., Rettig W. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am. J. Path. 142:1993;557-567.
5. Holm J., Hansen S.I., Hoier-Madsen M., Sondergaard K., Bzorek M. Folate receptor of human mammary adenocarcinoma. APMIS. 102:1994;413-419.
6. Rettig W., Garin-Chesa P., Beresford H., Oettgen H., Melamed M., Old L. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc. Nati. Acad. Sci. USA. 85:1988;3110-3114.
7. Ross J.F., Chaudhuri P.K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines - Physiologic and clinical applications. Cancer. 73:1994;2432-2443.
8. Weitman S.D., Lark R.H., Coney L.R., et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52:1992;3396-3401.
9. Reddy J.A., Haneline L.S., Srour E.F., Antony A.C., Clapp D.W., Low P.S. Expression and functional characterization of the beta-isoform of the folate receptor on CD34+ cells. Blood. 93:1999;3940-3948.
10. Antony A.C. Folate receptors. Ann. Rev. Nutr. 16:1996;501-521.
11. Wang X., Shen F., Freisheim J.H., Gentry L.E., Ratnam M. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem. Pharmacol. 44:1992;1898-1901.
12. Maziarz K.M., Monaco H.L., Shen F., Ratnam M. Complete mapping of divergent amino acids responsible for differential ligand binding of folate receptors alpha and beta. J. Biol. Chem. 274:1999;11086-11091.
13. Anderson R.G.W., Kamen B.A., Rothberg K.G., Lacey S.W. Potocytosis: sequestration and transport of small molecules by caveolae. Science. 255:1992;410-411.
14. Smart E.J., Mineo C., Anderson R.G. Clustered folate receptors deliver 5-methyltetrahydrofolate to cytoplasm of MA104 cells. J. Cell Biol. 134:1996;1169-1177.
15. Miotti S., Bagnoli M., Ottone F., Tomassetti A., Colnaghi M.I., Canevari S. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines. J. Cell. Biochem. 65:1997;479-491.
16. Ross J.F., Wang H., Behm F.G., et al. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer. 85:1999;348-357.
17. Bottero F., Tomassetti A., Canevari S., Miotti S., Menard S., Calnagi M.I. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res. 53:1993;5791-5796.
18. Luhrs C.A., Raskin C.A., Durbin R., et al. Transfection of a glycosylated phosphatidylinositol-anchored folate-binding protein complementary DNA provides cells with the ability to survive in low folate medium. J. Clin. Invest. 90:1992;840-847.
19. Sun X.L., Murphy B.R., Li Q.J., et al. Transduction of folate receptor cDNA into cervical carcinoma cells using recombinant adeno-associated virions delays cell proliferation in vitro and in vivo. J. Clin. Invest. 96:1995;1535-1547.
20. Toffoli G., Cernigio C., Russo A., Gallo A., Bagnoli M., Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer. 74:1997;193-198.
21. Lee R.J., Low P.S. Folate-targeted liposomes for drug delivery. Forum on liposome targeting. J. Liposome Res. 7:1997;455-466.
22. R.J. Lee, P.S. Low, Folate as a targeting device for protein utilizing folate receptor-mediated endocytosis, drug targeting, in: G.E. Francis, C. Delgado (Eds.), Series on Methods in Molecular Medicine, 25 (1999).
23. Wang S., Low P.S. Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. J. Control. Rel. 53:1998;39-48.
24. Reddy J.A., Low P.S. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit. Rev. Ther. Drug Carrier Syst. 15:1998;587-627.
25. Gruner B.A., Weitman S.D. The folate receptor as a potential therapeutic anticancer target. Invest. New Drugs. 16:1998;205-219.
26. Trippett T.M., Bertino J.R. Therapeutic strategies targeting proteins that regulate folate and reduced folate transport. J. Chemother. 11:1999;3-10.
27. Leamon C.P., Low P.S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. USA. 88:1991;5572-5576.
28. Leamon C.P., Low P.S. Membrane folate-binding proteins are responsible for folate-protein conjugate endocytosis into cultured cells. Biochem. J. 291:1993;855-860.
29. Crippa F., Buraggi G.L., Di Re E., et al. Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody. Eur. J. Cancer. 27:1991;724-729.
30. Crippa F., Bolis G., Seregni E., et al. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody 1-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur. J. Cancer. 31A:1995;686-690.
31. Paganelli G., Belloni C., Magnani P., et al. Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur. J. Nucl. Med. 19:1992;322-329.
32. Casalini P., Luison E., Menard S., Colnaghi M.I., Paganelli G., Canevari S. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J. Nucl. Med. 38:1997;1378-1381.
33. Front D., Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin. Nucl. Med. 25:1995;60-71.
34. van Leeuwen-Stok A.E., Drager A.M., Schuurhuis G.J., Platier A.W., Teule G.J., Huijgens P.C. Gallium 67 in the human lymphoid cell line U-715: Uptake, cytotoxicity, and intracellular localization. Int. J. Radiat. Biol. 64:1993;749-759.
35. Sohn M.H., Jones B.J., Whiting J.H.J., Datz F.L., Lynch R.E., Morton K.A. Distribution of gallium-67 in normal and hypotransferrinemic tumor-bearing mice. J. Nucl. Med. 34:1993;2135-2143.
36. Vera D.R. Gallium-labeled deferoxamine-galactosyl-neoglycoalbumin: A radiopharmaceutical for regional measurement of hepatic receptor biochemistry. J. Nucl. Med. 33:1992;1160-1166.
37. Green M.A. Metal radionuclides in diagnostic imaging by positron emission tomography (PET). Adv. Metals Med. 1:1993;75-114.
38. Smith-Jones P.M., Stolz B., Bruns C., et al. Gallium-67/gallium-68-[DFO]-octreotide - a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: Synthesis and radiolabeling in vitro and preliminary in vivo studies. J. Nucl. Med. 35:1994;317-325.
39. 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconj. Chem. 7:1996;56-62.
40. Mathias C.J., Wang S., Lee R.J., Waters D.J., Low P.S., Green M.A. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J. Nucl. Med. 37:1996;1003-1008.
41. Mathias C.J., Wang S., Waters D.J., Low P.S., Green M.A. Receptor-mediated targeting of Ga-67-deferoxamine-folate to folate receptor positive human KB tumor xenografts. Nucl. Med. Biol. 26:1999;23-25.
42. Wang S., Luo J., Lantrip D.A., et al. Design and synthesis of In-111-DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconj. Chem. 8:1997;673.
43. Mathias C.J., Wang S., Waters D.J., Turek J.J., Low P.S., Green M.A. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J. Nucl. Med. 39:1998;1579-1585.
44. Hwu P., Yang J.C., Cowherd Y.R., et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55:1995;3369-3373.
45. 99mTc-HYNIC-folate a novel receptor-based targeted radiopharmaceutical for tumor imaging. J. Nucl. Med. 40:1999;1563-1569.
46. Ilgan S., Yang D.J., Higuchi T., et al. Tc-99m-ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals. Cancer Biother. Radiopharm. 13:1998;427-435.
47. Mathias C.J., Hubers D., Trump D.P., Low P.S., Green M.A. Synthesis of Tc-99m-DTPA-folate and preliminary evaluation as a folate receptor-targeted radiopharmaceutical. Soc. Nucl. Med. 44th Ann. Meeting, San Antonio, TX :1997.
48. Lichtenberg D. Liposomes: Preparation, characterization, and preservation. Methods Biochem. Anal. 33:1988;337-462.
49. Gregoriadis G., Florence A.T. Liposomes in drug delivery-clinical, diagnostic and opthalmic potential. Drugs. 45:1993;15-28.
50. Garelli N., Vierling P. Incorporation of new amphiphilic perfluoroalkylated bipyridine platinum and palladium complexes into liposomes: Stability and structure-incorporation relationships. Biochim. Biophys. Acta. 1127:1992;41-48.
51. Litzinger D.C., Huang L. Phosphatidylethanolamine liposomes: Drug delivery, gene transfer and immunodiagnostic applications. Biochim. Biophys. Acta. 1113:1992;201-227.
52. Mayer L.D., Tai L.C.L., Ko D.S.C., et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 49:1989;5922-5930.
53. Gabizon A., Catane R., Uziely B., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54:1994;987-992.
54. Leserman L.D., Weinstein J.N., Blumenthal R., Terry W.D. Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells. Proc. Natl. Acad. Sci. USA. 77:1980;4089-4093.
55. Berinstein N., Matthay K.K., Papahadjopoulos D., Levy R., Sikie B.I. Antibody-directed targeting of liposomes to human cell lines: Role of binding and internalization on growth inhibition. Cancer Res. 47:1987;5954-5959.
56. Milhaud P.G., Machy P., Lebleu B., Leserman L. Antibody targeted liposomes containing poly(rI)·poly(rC) exert a specific antiviral and toxic effect on cells primed with interferons alpha/beta or gamma. Biochim. Biophys. Acta. 987:1989;15-20.
57. Park J.W., Hong K., Kirpotin D.B., Meyer O., Papahadjopoulos D., Benz C. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett. 118:1997;153-160.
58. Litzinger D.C., Huang L. Biodistribution and immunotargetability of ganglioside-stabilized dioleoylphosphatidylethanolamine liposomes. Biochim. Biophys. Acta. 1104:1992;179-187.
59. Klibanov A.L., Maruyama K., Beckerleg A.M., Torchilin V.P., Huang L. Activity of amphipathic poly(ethylene glycol)5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta. 1062:1991;142-148.
60. Liu D., Huang L. pH-sensitive, plasma-stable liposomes with relatively prolonged residence in circulation. Biochim. Biophys. Acta. 1022:1990;348-354.
61. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269:1994;3198-3204.
62. Gabizon A., Horowitz A.T., Goren D., et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconj. Chem. 10:1999;289-298.
63. Lee R.J., Low P.S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta. 1233:1995;134-144.
64. Wang S., Lee R.J., Cauchon G., Gorenstein D.G., Low P.S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA. 92:1995;3318-3322.
65. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269:1994;3198-3204.
66. Lee R.J., Wang S., Turk M.J., Low P.S. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery. Biosci. Rep. 18:1998;69-78.
67. Subbarao N.K., Parente R.A., Szoka F.C., Nadasdi L., Pongracz K. pH-dependent bilayer destabilization by an amphipathic peptide. Biochemistry. 26:1987;2964-2972.
68. Vogel K., Wang S., Lee R.J., Chmielewski J., Low P.S. Peptide-mediated release of folate-targeted liposome contents from endosomal compartments. J. Am. Chem. Soc. 118:1996;1581-1586.
69. Felgner P.L., Gadek T.R., Holm M., et al. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA. 84:1987;7413-7417.
70. Wagner E., Zenke M., Cotten M., Beug H., Birnstiel M.L. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. USA. 87:1990;3410-3414.
71. Behr J.P., Demeneix B., Loeffler J.P., Mutul J.P. Efficient gene transfer into mammalian primary endocrine with lipopolyamine-coated DNA. Proc. Natl. Acad. Sci. USA. 86:1989;6982.
72. Wagner E., Zatlooukal K., Cotten M., Kirkappos H., Mechtler K., Curiel D.T. Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc. Natl. Acad. Sci. USA. 89:1992;6099-6103.
73. Curiel D.T., Wagner E., Cotten M., Birnsteil M.L., Agarwal S., Li C.M. High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine conjugates. Hum. Gene Ther. 3:1992;147-154.
74. Cristiano R.J., Smith L.C., Woo S.L.C. Hepatic gene therapy: Adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. Proc. Natl. Acad. Sci. USA. 90:1993;2122-2126.
75. Cristiano R.J., Smith L.C., Kay M.A., Brinkley B.R., Woo S.L. Hepatic gene therapy: Efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc. Natl. Acad. Sci. USA. 90:1993;11548-11552.
76. Mislick K.A., Baldeschwieler J.D., Kayyem J.F., Meade T.J. Transfection of folate-polylysine DNA complexes: Evidence for lysosomal delivery. Bioconj. Chem. 6:1995;512-515.
77. Gottschalk S., Cristiano R.J., Smith L.C., Woo S.L.C. Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression. Gene Ther. 1:1994;185-191.
78. Lee R.J., Huang L. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J. Biol. Chem. 271:1996;8481-8487.
79. Lee R.J., Huang L. Lipidic vector systems for gene transfer. Crit. Rev. Ther. Drug Carrier Syst. 14:1997;173-206.
80. Guo W., Lee R.J. Targeted gene delivery via the folate receptor. Annu. Natl. Meeting of Am. Chem. Soc., Anaheim, CA :March, 1999;. Abstract.
81. Douglas J.T., Rogers B.E., Rosenfeld M.E., Michael S.I., Feng M., Curiel D.T. Targeting gene delivery by tropism-modified adenoviral vectors. Nat. Biotech. 14:1996;1574-1578.
82. Li S., Deshmukh H.M., Huang L. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm. Res. 15:1998;1540-1545.
83. Frankel A.E. Immunotoxin therapy of cancer. Oncology. 7:1993;69-78.
84. Leamon C.P., Low P.S. Selective targeting of malignant cells with cytotoxin-folate conjugates. J. Drug Targeting. 2:1994;101-112.
85. Leamon C.P., Low P.S. Cytotoxicity of momordin-folate conjugates in cultured human cells. J. Biol. Chem. 267:1992;24966-24971.
86. Leamon C.P., Pastan I., Low P.S. Cytotoxicity of folate-pseudomonas exotoxin conjugates toward tumor cells. J. Biol. Chem. 268:1993;24847-24854.
87. Coney L.R., Mezzanzanica D., Sanborn D., Casalini P., Colnaghi M.I., Zurawski V.R. Chimeric murin-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. Cancer Res. 54:1994;2448-2455.
88. Canevari S., Stoter G., Arienti F., et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst. 87:1995;1463-1469.
89. Canevari S., Mezzanzanica D., Mazzoni A., et al. Bispecific antibody targeted T cell therapy of ovarian cancer: Clinical results and future directions. J. Hematother. 4:1995;423-427.
90. Kranz D.M., Patrick T.A., Brigle K.E., Spinella M.J., Roy E.J. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate receptor-positive tumor cells for lysis. Proc. Natl. Acad. Sci. USA. 92:1995;9057-9061.
91. Ladino C.A., Charm R.V., Bourret L.A., Kedersha N.L., Goldmacher V.S. Folate-maytansinoids: target-selective drugs of low molecular weight. Int. J. Cancer. 73:1997;859-864.
92. Melani C., Figini M., Nicosia D., et al. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res. 58:1998;4146-4154.